Tourmaline Bio Inc. - Asset Resilience Ratio
Tourmaline Bio Inc. (TRML) has an Asset Resilience Ratio of 77.17% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Tourmaline Bio Inc.'s Asset Resilience Ratio has changed over time. Check TRML strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tourmaline Bio Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tourmaline Bio Inc. market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $207.81 Million | 77.17% |
| Total Liquid Assets | $207.81 Million | 77.17% |
Asset Resilience Insights
- Very High Liquidity: Tourmaline Bio Inc. maintains exceptional liquid asset reserves at 77.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tourmaline Bio Inc. Industry Peers by Asset Resilience Ratio
Compare Tourmaline Bio Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Tourmaline Bio Inc. (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Tourmaline Bio Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 73.72% | $227.80 Million | $309.00 Million | +44.13pp |
| 2023-12-31 | 29.59% | $62.23 Million | $210.29 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $9.10 Million | -- |
| 2021-12-31 | 89.63% | $225.36 Million | $251.42 Million | +3.30pp |
| 2020-12-31 | 86.33% | $131.90 Million | $152.78 Million | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more